Azapirones versus placebo for panic disorder in adults

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 11, 2013, Pages

  Guaiana, Giuseppe ^a   Barbui, Corrado ^b   Chiodo, Debbie ^c   Cipriani, Andrea ^d   Davies, Simon J C ^e   Imai, Hissei ^f   Koesters, Markus ^g  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF VERONA   (Italy)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d WARNEFORD HOSPITAL   (United Kingdom)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

^f KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALNESPIRONE; ANXIOLYTIC AGENT; AZAPIRONE DERIVATIVE; BINOSPIRONE; BUSPIRONE; GEPIRONE; IPSAPIRONE; LESOPITRON; PLACEBO; REVOSPIRONE; TANDOSPIRONE; UNCLASSIFIED DRUG; ZALOSPIRONE;

ADULT; ADVERSE DRUG REACTION; AGORAPHOBIA; ARTICLE; CLINICAL PROTOCOL; CLUSTER ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DSM-II; DSM-III-R; DSM-IV; EVIDENCE BASED MEDICINE; HUMAN; ICD-10; MONOTHERAPY; PANIC; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SIDE EFFECT; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 85041723812     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010828     Document Type: Article

References (44)

1. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?. Journal of the American Medical Association 2003;290:921-8.
2. Altman DG, Bland MJ. Detecting skewness for summary information. BMJ 1996;313:1200.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Arlington, VA: American Psychiatric Publishing, 1994.
4. American Psychiatric Association. American Psychiatric Association Practice Guidelines for the Treatment of Panic Disorder. American Psychiatric Association Practice Guideline for the Treatment of Panic Disorder. Arlington, VA: American Psychiatric Publishing, 2009.
5. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association forPsychopharmacology. Journal of Psychopharmacology 2005;19:567-96.
6. Batelaan NM, Van Balkom AJ, Stein DJ. Evidence-based pharmacotherapy of panic disorder: an update. International Journal of Neuropsychopharmacology 2011:1-13. [10.1017/S1461145711000800 [Epub ahead of print]]
7. Bhandari M, Busse JW, Jackowski D, Montori VM, Schünemann H, Sprague S, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. Canadian Medical Association Journal 2004;170:477-80.
8. Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Social Psychiatry and Psychiatric Epidemiology 1998;33:587-95.
9. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. Comparison of the indices and their use. Therapie 1999;54:405-11.
10. Broocks A, Meyer T, Opitz M, Bartmann U, Hillmer-Vogel U, George A, et al.5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo. European Neuropsychopharmacology 2003;13:153-64.
11. Bruce SE, Vasile RG, Goisman RM, Salzman C, Spencer M, Machan JT, Keller MB. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?. American Journal of Psychiatry 2003;160:1432-8.
12. Buchkowsky SS, Jewesson PJ. Industry sponsorship and authorship of clinical trials over 20 years. Annals of Pharmacotherapy 2004;38:579-85.
13. Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37-46.
14. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; Cape Town, South Africa. 2000 October 25-28.
15. Diaz MR, Chappell AM, Christian DT, Anderson NJ, McCool BA. Dopamine D3-like receptors modulate anxiety-like behavior and regulate GABAergic transmission in the rat lateral/basolateral amygdala. Neuropsychopharmacology 2011;36:1090-103.
16. Eaton WW, Kessler RC, Wittchen H-U, Magee WJ. Panic and panic disorder in the United States. American Journal of Psychiatry 1994;151:413-20.
17. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31:140-9.
18. Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. International Journal of Epidemiology 2002;31:72-6.
19. Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analysis. International Clinical Psychopharmacology 2005;20:49-52.
20. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2000;59:7-10.
21. Goisman RM, Warshaw MG, Steketee GS, Fierman EJ, Rogers MP, Goldenberg I, et al. DSM-IV and the disappearance of agoraphobia without a history of panic disorder: new data on a controversial diagnosis. American Journal of Psychiatry 1995;152:1438-43.
22. Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. American Journal of Psychiatry 2000;157:493-505.
23. Grant BF, Hasin DS, Stinson FS, Dawson DA, Goldstein RB, Smith S, et al. The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry 2006;67:363-74.
24. Guaiana G, Barbui C, Chiodo D, Cipriani A, Davies SJC, Koesters M. Antidepressants versus placebo for panic disorder in adults. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD010676]
25. Guaiana G, Barbui C, Chiodo D, Cipriani A, Davies SJC, Koesters M. Benzodiazepines versus placebo for panic disorder in adults. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD010677]
26. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons, 2011.
27. Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Archives of General Psychiatry 2006;63:415-24.
28. King M, Nazareth I, Levy G, Walker C, Morris R, Weich S, et al. Prevalence of common mental disorders in general practice attendees across Europe. British Journal of Psychiatry 2008;192:362-7.
29. Kishi T, Meltzer Y, Iwata N. Augmentation of antipsychotic drug action byazapirone 5-HT1A receptor partial agonists: a meta-analysis. International Journal of Neuropsychopharmacology 2013;16:1259-66.
30. Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 1964;5:397-408.
31. Lesch KP, Wiesmann M, Hoh A, Miiller T, Disselkamp-Tietze J, Osterheider M, et al.5-HTIA receptor-effector system responsivity in panic disorder. Psychopharmacology 1992;106:111-7.
32. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. British Medical Journal 2003;326:1167-70.
33. Moher D, Liberati A, TetzlaffJ, Altman DG, The PRISMA group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLOS Medicine 2009;6(6):e1000097.
34. Napoliello MJ, Domantay AG. Buspirone: a worldwide update. British Journal of Psychiatry 1991;159(Suppl 12):40-4.
35. Nash JR, Sargent PA, Rabiner EA, Hood SD, Argyropoulos SV, Potokar JP, et al. Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study. British Journal of Psychiatry 2008;193:229-34.
36. National Institute for Health and Care Excellence. Generalised Anxiety Disorder and Panic Disorder (With or Without Agoraphobia) in Adults [CG113]. London: National Institute for Health and Care Excellence, 2011.
37. Parks CL, Robinson PS, Sibille E, Shenk T, Toth M. Increased anxiety of mice lacking the serotonin1A receptor. Proc Natl Acad Sci USA 1998;95:10734-9.
38. Payer D, Bolleau I, Guranda M, GraffA, Nakajima S, Meyer J, et al. Buspirone occupancy of D2/3 dopamine receptors in humans measured by positron emission tomography. Proceedings of the College on Problems of Drug Dependence, 75th Annual Scientific Meeting, San Diego, CA. 15-20 June 2013.
39. Pompoli A, Furukawa TA, Imai H, Tajika A, Efthimiou O, Salanti G. Psychological therapies for panic disorder with or without agoraphobia in adults. Cochrane Database of Systematic Reviews (in press).
40. Starcevic V. Anxiety Disorders in Adults: A Clinical Guide. Oxford, UK: Oxford University Press, 2009.
41. Stein M, Steckler T, Lightfoot JD, Hay E, Goddard AW. Pharmacologic treatment of panic disorder. Current Topics in Behavioral Neurosciences 2010;2:469-85.
42. Tauscher J, Bagby RM, Javanmard M, Christensen BK, Kasper S, Kapur S. Inverse relationship between serotonin 5-HT(1A) receptor binding and anxiety: a [(11)C]WAY-100635 PET investigation in healthy volunteers. Am J Psychiatry 2001;158:1326-8.
43. Wade AG. Antidepressants in panic disorder. International Clinical Psychopharmacology 1999;14(Suppl 2):13-7.
44. Watanabe N, Churchill R, Furukawa TA. Combined psychotherapy plus benzodiazepines for panic disorder. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD005335.pub2]